SC presses Centre on proposed 16% medicine MRP cap after cancer-drug markup
The Supreme Court cited a cancer drug bought by retailers for ₹3,520 and sold to patients for ₹22,427 as it pressed the government on a 16% cap on medicine MRPs. The proposal remains pending; the next hearing is scheduled for October 12.
The development
The Supreme Court pressed the government on a 16% cap on medicine MRPs, citing a cancer drug sold to patients for ₹22,427 after retailers paid ₹3,520. The court listed the matter for further hearing on October 12.
The numbers
- 16%
- ₹3,520
- ₹22,427
- October 12
Why it matters to operators and investors
Factor possible medicine-price regulation into pharmacy deal scenarios and valuations, while avoiding assumptions that the proposed cap will take effect.
What to watch next
- The government's response and any revised proposal at the October 12 hearing.
- Whether the court asks for a firm timetable or accepts a request for more time.
- Any draft notification clarifying covered medicines, the cap's calculation, exemptions, and enforcement.
- Public statements from pharmacy associations, drugmakers, or regulators on likely effects on supply and retail margins.
- Pharmacy chains and trade groups assess exposure by medicine and prepare representations on implementation and margins.
- Retailers monitor supplier price lists and trade discounts for changes ahead of any formal rule.
- Larger chains strengthen SKU-level pricing and compliance systems in case the proposal advances.
The counter-case
This is not an enacted cap: the proposal is pending, and the court's questions do not establish that the government will adopt it or what any final rule would cover. The cited price gap is one example, not evidence of sector-wide pharmacy economics; MRP is a ceiling, not necessarily the price patients pay, and the retailer's purchase price alone does not establish the full distribution margin.